CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
(MRD Trial)
Recruiting at 28 trial locations
ND
Overseen ByNSABP Department of Site and Study Management Department of Site and Study Management
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Exact Sciences Corporation
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Trial Summary
What is the purpose of this trial?
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Eligibility Criteria
Inclusion Criteria
Diagnosis of carcinoma of the colon or rectum (patients with lymphomatous, sarcomatous, or neuroendocrine features are not eligible).
in the opinion of the surgeon, all grossly visible tumor was completely resected ("curative resection")
histologic evaluation by the pathologist confirms the margins of the resected specimens are not involved by malignant cells.
See 5 more
Treatment Details
Interventions
- MRD
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Stage ll or lllExperimental Treatment1 Intervention
Patients with stage ll or lll colorectal cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Exact Sciences Corporation
Lead Sponsor
Trials
36
Recruited
282,000+
NSABP Foundation Inc
Collaborator
Trials
89
Recruited
140,000+
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.